For the treatment of chronic hepatitis B in adults
Natco Pharma announced that it is one of the first companies to launch a generic version of Tenofovir Alafenamide, TAF, 25 mg, a once-daily tablet for the treatment of chronic hepatitis B in adults, under its brand TAFNAT, in India. The drug TAF demonstrates comparable efficacy, with an enhanced renal and bone safety profile as compared to earlier formulation of tenofovir (tenofovir disoproxil fumarate).TAFNAT is manufactured under license from Medicines Patent Pool (MPP) and Gilead Sciences. Natco priced its generic medicine of TAFNAT at Rs Rs 1900/- for a monthly pack of 30 tablets for the India market.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
